Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Targepeutics Inc. is currently processing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is under the review of 1 distinct examiner, REYNOLDS, FRED H, who holds the 1 busiest examiner pending action. The involvement of 1 distinct art unit indicates a focused technical scope for the company's current patent application.
Because there is only 1 pending office action, the prosecution strategy is entirely centered on the interaction with REYNOLDS, FRED H. The applicant's success in the Biotechnology & Pharmaceuticals sector currently depends on addressing the specific requirements of this 1 distinct examiner. This concentrated activity allows for a dedicated response to the examiner's concerns but lacks the broader data points available to larger portfolios.
The use of 1 distinct art unit suggests that the technology is being evaluated within a specific division of the patent office. With 1 busiest examiner pending action to manage, the company's legal team can focus on the specific prior art and legal issues raised by REYNOLDS, FRED H. This streamlined approach is common for companies with a very specific technical focus in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294303 | METHODS OF TREATING MALIGNANT GLIOMAS | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294303 | METHODS OF TREATING MALIGNANT GLIOMAS | REYNOLDS, FRED H | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Feb 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTargepeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Fred H Reynolds has the most, with 1 of Targepeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
